45 Results for "

DXd

" in MedChemExpress (MCE) Product Catalog:
Products (45)

45 Results for "DXd" in MCE Product Catalog:

Cat. No.: HY-138298C
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR4); DS-8201 (DAR4); DS-8201a (DAR4)
Research Areas:  

Cancer

Trastuzumab deruxtecan (DAR4) (T-DXd (DAR4); DS-8201 (DAR4); DS-8201a (DAR4)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 4. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
loading...
    loading...
Cat. No.: HY-138298D
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR6); DS-8201 (DAR6); DS-8201a (DAR6)
Research Areas:  

Cancer

Trastuzumab deruxtecan (DAR6) (T-DXd (DAR6); DS-8201 (DAR6); DS-8201a (DAR6)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 6. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
loading...
    loading...
Cat. No.: HY-P81054
Synonyms: DXd, OQM5SD32BQ, UNII-OQM5SD32BQ, Exatecan derivative, Exatecan derivative for ADC

Host:  

Mouse

Application:  

ELISA

Reactivity:  

Species independent

loading...
    loading...
Cat. No.: HY-188015
CAS No.: 3086791-85-4
Target:  

ADC Payloads

Research Areas:  

Cancer

DBCO-PEG4-GGFG-Triptolide is a triptolide-based antibody-drug conjugate (ADC) payload, consisting of a DBCO click chemistry reactive group, a PEG4 linker, a cathepsin-cleavable GGFG peptide segment, and triptolide. DBCO-PEG4-GGFG-Triptolide binds to antibodies via glycosylation conjugation, releases active triptolide intracellularly to exert cytotoxic effects, and is commonly used in combination with camptothecin-class toxins (Exatecan (HY-13631) / DXd (HY-13631D)) for the preparation of dual-toxin ADCs .
loading...
    loading...
Cat. No.: HY-185816
TQB2102 is a bispecific epitope antibody-drug conjugate targeting HER2, composed of the antibody Rolditamig (HY-P992130) and the toxin molecule Deruxtecan-d2 (HY-13631ES3). TQB2102 binds to the ECD2 and ECD4 domains of HER2, promotes its own internalization by HER2-expressing cells, and delivers deuterated DXd payload to inhibit topoisomerase I. TQB2102 induces antibody-dependent cellular cytotoxicity, DNA damage, bystander killing activity, and inhibits cancer cell proliferation. TQB2102 can be used in research related to various cancers including metastatic breast cancer, colorectal cancer, and gastric/gastroesophageal junction adenocarcinoma .
loading...
    loading...